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Background: Accumulated evidence reveals that cyclooxygenase-2 (COX-2) was overexpressed in eutopic
endometrium of endometriosis, which may play a critical role in the pathogenesis of endometriosis. However, few
studies have been performed to explore the molecular mechanisms underlying the abnormal high expression of
COX-2 in endometriosis. Considering the fact that a number of recent studies have shown DNA methylation
affecting some genes in endometriosis, the present study was therefore aimed to determine whether the observed
high expression COX-2 in endometriosis is caused by the hypomethylation of CpG island within the promoter of
this gene.
Methods: The endometrial tissues were collected from 60 women with endometriosis (endometriosis group) and
20 women without endometriosis (control group). The methylation status of COX-2 was examined by methylation
specific PCR. Quantitative real-time RT-PCR was performed to measure COX-2 mRNA level in endometrial tissues.
Results: The frequency of promoter hypermethylation of COX-2 was lower in eutopic endometrium of the
endometriosis group (41.7%) than that in the control group (75.0%), P< 0.05. COX-2 mRNA level in the eutopic
endometrium of the endometriosis group was 2.61-fold higher than that in the control group (P< 0.01). COX-2
mRNA level in unmethylated endometrium of the endometriosis group or the control group was 2.39-fold and
2.66-fold, respectively, higher than that in the methylated endometrium of the same group (P< 0.01).
Conclusions: The hypomethylation within the promoter of COX-2 may be responsible for the elevated gene
expression in eutopic endometrium of endometriosis.
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Endometriosis is an estrogen-dependent gynecological
disorder that affects 6-10% of women of reproductive
age. It is characterized histologically by the presence of
endometrial tissue at sites outside of the uterine cavity,
primarily on the pelvic peritoneum and ovaries, result-
ing in severe pelvic pain, pain during intercourse, and
infertility [1,2]. To date, the etiology and pathogenesis* Correspondence: wangdb@sj-hospital.org
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reproduction in any medium, provided the orof endometriosis remain largely unknown. Endometri-
osis is a benign gynecological disease with malignant
behaviors, such as enhanced proliferation and cell inva-
sion, ectopic implantation of distant organs similar to
the tumor metastasis. The eutopic endometrium of
patients with endometriosis has various alterations
compared with endometrium of healthy women [3].
Aberrant expression of genes in eutopic endometrium
was reported be involved in cell adhesion, invasion, and
angiogenesis, therefore it was quite critical to the
pathogenesis of endometriosis [4-6].
The ectopic endometrium of endometriosis often
behaves unpredictably; it can vary from microscopic focitd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The cases of the endometriosis group and the
control group in different phase of menstrual cycle (n)
Phase of menstrual cycle EMs group Control group χ2 P
Early secretory 20 7 0.032 0.984
Mid secretory 27 9
Late secretory 13 4
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to difficulties in research, diagnosis, and treatment. Euto-
pic endometrium of endometriosis is readily available and
gene alteration in the eutopic endometrium can be easily
detected. Identification endometriosis-related genes in
eutopic endometrium will further reveal the pathogenesis
of endometriosis and offer the basis for targeted gene
diagnosis and therapy of endometriosis. In the previous
study, we identified 10 up-regulated genes in the eutopic
endometrium of endometriosis during the secretory phase
using cDNA-RDA and found that cyclooxygenase-2
(COX-2) was one of the up-regulated genes [7]. As the
key enzyme in the conversion of arachidonic acid to pros-
taglandins (PGs), COX-2 can be induced by growth fac-
tors, oncogenes, and tumor promoters, and has been
mainly associated with the inflammatory response [8]. Its
elevated expression in the eutopic endometrium has also
been reported to be associated with endometriosis [9,10].
However, the underlying mechanism of overexpression of
COX-2 in eutopic endometrium of endometriosis has not
been well defined.
DNA methylation is an epigenetic phenomenon known
to play a critical role in the regulation of gene expression
in development, differentiation, and complex diseases,
with cancer being the most prominent example [11,12].
Moreover, aberrant methylation of promoter CpG island
of the COX-2 has been known as an alternative mechan-
ism of its abnormal expression and contributes to the car-
cinogenesis in many human cancers [13,14]. Recently,
DNA methylation has also been shown to affect a num-
ber of genes in endometriosis [15]. These findings lead us
to investigate whether aberrant expression of the COX-2
in eutopic endometrium of endometriosis is caused by
aberrant methylation of the COX-2 CpG island. The nu-
clear factor responsible for the interleukin-6 expression
(NF-IL6) site as one of the critical cites of the COX-2
promoter plays an important role in the regulation of
COX-2 expression [16]. In the present study, we investi-
gated, for the first time, that whether the observed ele-
vated expression of the COX-2 gene in endometriosis is
associated with the hypomethylation of NF-IL6 site
within the promoter of this gene.
Methods
Patients and specimens
Eutopic endometrium samples were collected from 60
patients with an average age of 43.65 ± 3.99 years, who
underwent hysterectomy due to endometriosis stages III
and IV according to the Revised American Fertility Soci-
ety Classification for Endometriosis at the Department of
Obstetrics and Gynecology, Shengjing Hospital of China
Medical University. For controls, endometrium samples
were obtained from 20 women with an average age of
43.20 ± 2.87 years, who underwent total hysterectomydue to cervical intraepithelial neoplasia III in the same
hospital, surgically confirming without endometriosis.
Diagnosis was confirmed with histopathological examin-
ation in all cases. All subjects presented regular men-
strual cycles (cycle length was approximately 25 to
32 days). Cycle stage was estimated according to the date
of the last menstrual phase or by histological evaluation
[17]. All specimens were obtained in the secretory phase
of the menstrual cycle (days 15 to 28) in our study. As
shown in Table 1, there was no difference between the
two groups with respect to the cycle phase. None of these
patients had received any GnRH analogue, antibiotics,
radio-, chemo-, or hormone therapy in the last 6 months
prior to the surgery. Endometrium samples were gathered
within 10–15 min after hysterectomy and immediately
frozen in liquid nitrogen and then preserved in −80°C
refrigerator until further use. Written informed consent
was obtained before surgical procedures, including a
consent form and protocol approved by the Institutional
Review Boards of China Medical University.
Methylation specific PCR (MSP)
Genomic DNA was extracted from endometrial tissues
by using the TIANamp Genomic DNA Kit (Tiangen Bio-
tech Co., Ltd., Beijing, China) according to the manufac-
turer’s instructions. Then, 1 μg genomic DNA was
modified by sodium bisulfite with the CpGenomeTM
DNA Modification Kit (Chemicon, Billerica, MA, USA).
This modification converts unmethylated cytosine to
uracil and leaves 5-methyl cytosine unchanged. Briefly,
20 μL of genomic DNA was treated with 550 μL of a
mixed solution of 3.5 M sodium bisulfite/1 mM hydro-
quinone (pH 5.0). After incubation at 55°C for 16 h, the
treated DNA was purified and desulfonated with 0.3 M
NaOH. The modified DNA obtained was ethanol-
precipitated and dissolved in 50 μL of Tris-EDTA buffer.
The primers used for the methylated COX-2 gene-
promoter regions were as follows: (a) COX-2 F, 50-GA
AGCGTTCGGGTAAAGATTGC-30 and (b) COX-2R,
50-AAATTACGTAAACCCGATAAAA-30. Primers for
unmethylated COX-2 were as follows: (a) COX-2 F,
50-TGGAAGTGTTTGGGTAAAG-30 and (b) COX-2R,
50-AAAATTACATAAACCCAATA-30. To exclude false-
positive and false-negative results, universal unmethylated
DNA and universal methylated DNA were purchased
from Chemicon and served as controls.
Figure 1 Representative samples of MSP analyses of DNA
samples from the endometrial tissues of the endometriosis and
control groups. Lanes: Marker, molecular weight marker; N,
universal unmethylated DNA; P, universal methylated DNA. U/M, PCR
products with primers specific for unmethylated and methylated
sequences, respectively.
Table 2 The relationship between the methylation status
of COX-2 promoter and its mRNA expression in
endometrial tissues (x ± s, n)
mRNA level mRNA level(M) mRNA level(U)
EMs group 2.95 ± 1.35a 1.63 ± 0.42b 3.90 ± 0.93b
(n = 60) (n = 25) (n = 35)
Control group 1.13 ± 0.65a 0.80 ± 0.19c 2.13 ± 0.49c




mRNA level, mRNA level of COX-2 in endometrial tissues; mRNA level(M),
mRNA level of COX-2 in methylated endometrial tissues; mRNA level(U), mRNA
level of COX-2 in methylated endometrial tissues.
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Total RNA was isolated by using the RNAsimple total
RNA kit (Tiangen, China) according to the manufacturer’s
instructions. One microgram total RNA was reverse tran-
scribed using the TIANScript RT Kit (Tiangen, China).
Quantitative real-time RT-PCR was performed using SYBR
green (Tiangen, China) on ExicyclerTM 96 Real-Time
Quantitative Thermal Block (Bioneer, Daejeon, Korea). The
specificity of the PCR was confirmed by examining the dis-
sociation reaction plot subsequent to real-time RT-PCR.
GAPDH served as the constitutive control. Forward and re-
verse primers were 50-GAATCATTCACCAGGCAAATT
G-30 and 50-TCTGTACTGCGGGTGGAACA-30 for COX-
2, respectively; 50-GCACCGTCAAGGCTGAGAAC-30 and
50-ATGGTG-GTGAAGACGCCAGT−30 for GAPDH, re-
spectively. PCR reactions of each sample were done in trip-
licate. We took the average value of the control group as
internal control. Gene expression levels were calculated
and determined using the threshold cycle (CT) method
(2-ΔΔCT method) [6].
Statistical analysis
Statistical analysis was performed using the SPSS11.0 soft-
ware. Differences of the methylation frequencies in the
groups were analyzed using the χ2 test. Differences of
mRNA level between the two groups were analyzed using
the Student’s t-test. Values were expressed as mean+SEM.
A P value <0.05 was considered statistically significant.
Results
Methylation status of cox-2 in endometrial tissues
To determine the methylation status of the NF-IL6 site
within COX-2 promoter in endometriosis, endometrial
tissues from 60 patients with endometriosis and 20 con-
trols without endometriosis were examined by methyla-
tion specific PCR (MSP). MSP showed that 41.7% (25/
60) of endometrial tissues in the endometriosis group
and 75% (15/20) of endometrial tissues in the control
group showed the hypermethylation, respectively
(χ2 = 6.67, P= 0.01). Representative examples are shown
in Figure 1.
COX-2 mRNA expression in endometrial tissues
To determine the correlation between DNA methylation
and COX-2 expression in endometrial tissues, we evalu-
ated the mRNA level of COX-2 in endometrial tissues be-
tween the endometriosis group and the control group by
using quantitative real-time RT-PCR. As shown in Table 2,
COX-2 mRNA level in endometrial tissues of the endo-
metriosis group was 2.61-fold higher than that in the con-
trol group (P< 0.01). COX-2 mRNA level of the
unmethylated endometrial tissues was 2.39-fold higher
than the methylated endometrial tissues in the endometri-
osis group (P< 0.01). Compared to the methylatedendometrial tissues, COX-2 mRNA level of the unmethy-
lated endometrial tissues was 2.66-fold higher in the con-
trol group (P< 0.01). These data suggest that
demethylation of COX-2 promoter may be responsible
for its abnormally high expression in eutopic endomet-
rium of endometriosis.
Discussion
In the present study, we provided experimental evidence
that the frequency of hypermethylation of NF-IL6 site
within COX-2 promoter in the endometrium of the
endometriosis group was lower than that of the control
group (P= 0.01). However, COX-2 mRNA level in the
endometrium of the endometriosis group was higher
than that in the control group (P < 0.01). In addition, we
found that COX-2 mRNA level of the unmethylated
endometrial tissues in endometriosis group was 2.39-fold
higher than the methylated endometrial tissues in the
same group (P < 0.01). Compared to the methylated
endometrial tissues in the control group, COX-2 mRNA
level of the unmethylated endometrial tissues in the
same group was 2.66-fold higher (P < 0.01). Our data
showed that the hypomethylation of NF-IL6 site within
COX-2 promoter may be responsible for the elevated
gene expression in eutopic endometrium of endometri-
osis. Meanwhile, we observed that there was also a
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tween unmethylated endometrium of patients with
endometriosis and unmethylated endometrium of con-
trols. Thus, the authors speculated that other mechan-
isms, except hypomethylation COX-2 promoter, may be
also participate in elevated COX-2 expression in endo-
metriosis [18].
Endometriosis is an estrogen-dependent gynecological
disease causing pelvic pain and infertility. Up to now, the
pathophysiology of endometriosis remains an enigma. In
the previous study, other workers [9,10] and us [7] have
demonstrated that COX-2 was one of the up-regulated
genes in the eutopic endometrium of endometriosis. The
elevated expression of COX-2 resulted in the production
of PGE2, not only regulating cell proliferation, apoptosis,
migration, invasion, angiogenesis, and immunomodula-
tion, but also increasing the expression of aromatase and
its activity, which lead to higher estradiol formation
[19,20]. Additionally, PGE2 is also a potent mediator of
pain and inflammation in endometriosis [21]. Thus,
COX-2 overexpression that lead to higher levels of pros-
taglandins may be probably the key mechanism causing
endometriosis-related severe dysmenorrheal and inflam-
mation. It was reported that inhibition of COX-2 expres-
sion prevented establishment of endometriosis and
decreased the size and number of endometriotic lesions
in different animal models [22,23]. More importantly,
The Food and Drug Administration approved that select-
ive COX-2 inhibitors with milder side effects (for ex-
ample, rofecoxib and valdecoxib) can be used for the
treatment of primary dysmenorrhea, and their long-term
administration could potentially reduce the chronic pel-
vic pain associated with endometriosis [2]. In the present
study, we further demonstrated that COX-2 mRNA level
in eutopic endometrium of the endometriosis group was
significantly higher than that in the control group.
Increased COX-2 expression and PGE2 production were
believed to be strongly correlated with pathophysiology
and pathogenesis of endometriosis. However, how COX-
2 expression is regulated in detail remains unknown in
eutopic endometrium of endometriosis.
Besides the well-known genetic alterations, changes in
DNA methylation have been recognized as one of the
most common molecular alterations in human neoplasia
[24]. Recent studies have indicated that an epigenetic dis-
order may play a role in the pathophysiology of endomet-
riosis [25]. For instance, Xue et al. have reported that
DNA hypomethylation of estrogen receptor 2 (ESR2) and
steroidogenic factor-1 (SF-1) were responsible for their
strikingly elevated level in endometriosis [26,27]. Add-
itionally, DNA hypermethylation and suppressed expres-
sion of HOXA10 have been shown in the endometrium of
women with endometriosis [28]. However, little is known
about the relationship between the methylation status ofthe CpG island with the COX-2 promoter and COX-2 ex-
pression in eutopic endometrium of endometriosis.
There are 51 CpG sites in the promoter region of
COX-2 gene from −590 to +186 nt. It is generally
accepted that COX-2 expression is regulated predomin-
antly by the activation of three transcription factors: the
nuclear factor-kB (NF-kB), the nuclear factor for
interleukin-6 expression (NF-IL6), and the cyclic AMP
response element (CRE) [29,30]. Song et al. [31]
reported that the constitutively active COX-2 promoter
activity, which was induced by using the NF-IL6 and
CRE elements, was completely blocked by heavy methy-
lation of the COX-2 CpG island in gastric carcinoma
cells. However, treatment with demethylating agents ef-
fectively reactivated the expression of COX-2. Hence,
there is a substantial possibility that the aberrant methy-
lation of CpG sites at critical sites may be one of the
mechanisms regulating the COX-2 transcription. In par-
ticular, Tamura et al. [32,33] reported that the NF-IL6
site was involved in inducing COX-2 gene transcription
of endometrial stromal cells. Therefore, we examined
the methylation status of NF-IL6 site within the COX-2
promoter by methylation specific PCR. Our data showed
the frequency of hypermethylation of the NF-IL6 site
within COX-2 promoter in eutopic endometrium of the
endometriosis group was lower compared to the control
group, which was inversely related to the COX-2 expres-
sion. Meanwhile, we found that COX-2 mRNA level of
the unmethylated endometrial tissues in the endometri-
osis group and control group was significantly higher
than the methylated endometrial tissues of each corre-
sponding group. Although the early, middle, and late
secretory phases have very distinct characteristics and
COX-2 expression may vary according to the menstrual
cycle. However, our data showed that there was no dif-
ference between the two groups with respect to the cycle
phase. These results showed that the hypomethylation
within the promoter of COX-2 may be responsible for
the elevated gene expression in eutopic endometrium of
endometriosis, which further suggested a possibility that
endometriosis was an epigenetic disease.
Several limitations of this study need to be pointed
out. First, our study was confined to patients with stages
III and IV endometriosis. Whether or not the same
methylation alterations also occur in early stages of
endometriosis await for further studies. Second, we did
not detect the methylation of COX-2 in matched endo-
metriotic tissues, which may further demonstrated the
role of aberrant methylation of COX-2 in the pathogen-
esis of endometriosis.
In conclusions, our present study demonstrated for
the first time that DNA hypomethylation of the NF-IL6
site within the promoter of the COX-2 gene may be a
key mechanism for its abnormally elevated expression in
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demethylation of the NF-IL6 site within the COX-2 pro-
moter causes the increased expression of COX-2 in
eutopic endometrium of endometriosis needs further
study. Further study of similar epigenetic changes may
prove to be extremely useful in the diagnosis and treat-
ment of endometriosis in the future.
Conclusions
To the best of our knowledge, our results indicated for
the first time that the hypomethylation of NF-IL6 site
within COX-2 promoter may be responsible for the ele-
vated gene expression in eutopic endometrium of endo-
metriosis. Although the biological functions associated
with the presence of demethylation-mediated transcrip-
tional activation of the COX-2 gene are not clear, our
results showed the DNA hypomethylation of the COX-2
CpG island was involved in the pathogenesis of endo-
metriosis, which also provide an additional evidence that
endometriosis ultimately may be an epigenetic disease.
Further study of similar epigenetic changes may prove to
be extremely useful in the diagnosis and treatment of
endometriosis in the future.
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